PPIB and Alzheimer disease: In comparison, we have recently reported that long-term treatment regimens with liraglutide, using similar doses (100–500 μg/kg/day, s.c.)with equivalent dosing periods (4–5 months) and stereological measures, showed neuroprotective effects in two mouse models of AD without β-amyloid plaque pathology, i.e. non-transgenic SAMP8 mice [34] and hTauP301 transgenic mice [35].